mTOR inhibitor introduce disitamab vedotin (RC48-ADC) rechallenge microtubule-chemotherapy resistance in HER2-low MBC patients with PI3K mutation

mTOR inhibitor introduce disitamab vedotin (RC48-ADC) rechallenge microtubule-chemotherapy resistance in HER2-low MBC patients with PI3K mutation

This study aimed to explore the efficacy and potential mechanisms of rechallenge therapy with microtubule-targeting agents (MTAs) in patients with HER2-low metastatic breast cancer (MBC). We performed a systematic review to investigate the rechallenge treatment concept in the field of HER2-low MBC t...

Full description

Bibliographic Details
Main Authors:	Ye Hu, Fengxi Chen, Siwen Sun, Lingzhi Xv, Xueqing Wang, Meiling Wang, Shanshan Zhao, Zuowei Zhao, Man Li
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-01-01
Series:	Frontiers in Oncology
Subjects:	HER2-low metastatic breast cancer disitamab vedotin (RC48) microtubule targeting agents (MTAs) rechallenge mTOR inhibitor PIK3CA mutation
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1312634/full

Similar Items

Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy
by: Fan Shi, et al.
Published: (2022-12-01)

Disitamab Vedotin (RC48) for HER2-positive advanced breast cancer: a case report and literature review
by: Yang Li, et al.
Published: (2023-11-01)

Neoadjuvant therapy with Disitamab vedotin in treating muscle-invasive bladder cancer: A case report
by: Haijun Huang, et al.
Published: (2023-04-01)

Efficacy of Disitamab Vedotin in a heavily pre-treated HER2 positive lung adenocarcinoma patient: case report and literature review
by: Xiangjun Qi, et al.
Published: (2022-09-01)

Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium
by: Jiazheng Yu, et al.
Published: (2023-07-01)

Real‐world effectiveness and safety of RC48‐ADC alone or in combination with PD‐1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: A multicenter, retrospective clinical study
by: Jingwei Xu, et al.
Published: (2023-12-01)

PEGylated Liposomal Doxorubicin Rechallenge following Doxorubicin-induced Pancreatitis
by: Luke Ardolino, et al.
Published: (2020-12-01)

Rechallenge of voriconazole successfully tolerated after hepatic toxicity
by: O. Narumoto, et al.
Published: (2020-01-01)

Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma
by: Nobutaka Nishimura, et al.
Published: (2022-09-01)

Improvement of Cutaneous Anaplastic Large Cell Lymphoma by Brentuximab Vedotin Monotherapy
by: Takashi Onaka, et al.
Published: (2018-05-01)

Immunotherapy Resumption/Rechallenge in Melanoma Patients after Toxicity: Do We Have Another Chance?
by: Sofia España Fernandez, et al.
Published: (2023-03-01)

The successful management of SJS/TEN secondary to enfortumab vedotin therapy
by: Rhea Singh, BS, et al.
Published: (2022-06-01)

Brentuximab vedotin in the treatment of relapsed and refractory forms of Hodgkin lymphoma
by: E A Demina
Published: (2016-06-01)

Melanoma: BRAFi Rechallenge
by: Christoforos S. Kosmidis, et al.
Published: (2023-05-01)

The Effectiveness of Cancer Immune Checkpoint Inhibitor Retreatment and Rechallenge—A Systematic Review
by: Adrian Perdyan, et al.
Published: (2023-07-01)

Ofloxacin-ornidazole fixed-dose combination medication-induced pancreatitis with positive rechallenge
by: Nikhil Bush, et al.
Published: (2020-01-01)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
by: Qingli Cui, et al.
Published: (2022-01-01)

Current and Emerging Treatments for Urothelial Carcinoma: A Focus on Enfortumab Vedotin
by: Shafique MA, et al.
Published: (2023-07-01)

Successful rechallenge with cetuximab after progression with nivolumab for recurrent cervical lymph node metastasis from carcinoma of the tongue
by: Yasuyuki Asada, et al.
Published: (2021-07-01)

Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer
by: Davide Ciardiello, et al.
Published: (2021-04-01)

Cetuximab Rechallenge and Monotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck
by: Greg Knutzen, et al.
Published: (2015-11-01)

Brentuximab vedotin therapy for cutaneous lesions in T-prolymphocytic leukemia: a case report
by: Jordan Senchak, et al.
Published: (2016-09-01)

Desquamative extravasation reaction secondary to enfortumab vedotin
by: Akshay N. Pulavarty, MD, MPH, et al.
Published: (2024-04-01)

Disitamab vedotin in combination with immune checkpoint inhibitors for locally and locally advanced bladder urothelial carcinoma: a two-center’s real-world study
by: Yongbao Wei, et al.
Published: (2023-08-01)

Immune Checkpoint Inhibitors-Associated Myocarditis: Diagnosis, Treatment and Current Status on Rechallenge
by: Federica Frascaro, et al.
Published: (2023-12-01)

Efficacy of NSCLC Rechallenge with Immune Checkpoint Inhibitors following Disease Progression or Relapse
by: Maria Effrosyni Livanou, et al.
Published: (2024-03-01)

Lenvatinib rechallenge in a patient with advanced thymic carcinoma: A case report
by: Yuto Terashima, et al.
Published: (2022-12-01)

Immediate Response to Brentuximab Vedotin in a Patient with Localized MF-LCT
by: Agnieszka Giza, et al.
Published: (2023-07-01)

Long-term Survival after Lapatinib Rechallenge in Isolated Brain Metastasis of HER2-positive Breast Cancer
by: Bülent Karagöz, et al.
Published: (2015-01-01)

Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2-low advanced or metastatic gastric cancer: a multicenter real-world study
by: Caiyun Nie, et al.
Published: (2023-12-01)

Safety and efficacy of cyclin-dependent kinase inhibitor rechallenge following ribociclib-induced limiting hypertransaminasemia
by: Jesús Fuentes-Antrás, et al.
Published: (2020-12-01)

Brentuximab vedotin is the first target drug in the treatment of hodgkin lymphoma
by: G. S. Tumyan
Published: (2018-11-01)

Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date
by: Moussa M, et al.
Published: (2021-02-01)

Disitamab Vedotin (RC48) combined with bevacizumab for treatment of HR-negative/HER2-positive metastatic breast cancer with liver and brain involvement: A case report
by: Fei Qu, et al.
Published: (2023-08-01)

Bilateral Anterior Subcapsular Cataract Development Following Initiation of Enfortumab Vedotin
by: Thibodeau A, et al.
Published: (2021-10-01)

Genetic and molecular analysis of stem rot (Sclerotinia sclerotiorum) resistance in Brassica napus (canola type)
by: Muhammad Azam Khan, et al.
Published: (2023-09-01)

Effectiveness of EGFR‐TKI rechallenge immediately after PD‐1 blockade failure
by: Kyoichi Kaira, et al.
Published: (2021-03-01)

First Evidence of Activity of Enfortumab Vedotin on Brain Metastases in Urothelial Cancer Patients
by: Christof Vulsteke, et al.
Published: (2023-03-01)

TARGETED THERAPY WITH BRENTUXIMAB VEDOTIN IN RELAPSED AND REFRACTORY FORMS OF CLASSICAL HODGKIN LYMPHOMA
by: E. A. Demina
Published: (2017-11-01)

Use of Brentuximab Vedotin in a Non-HIV Patient with Primary Effusion Lymphoma
by: Joana Ferra, et al.
Published: (2021-02-01)